Lipid nanoparticles, as a key delivery technology in modern biopharmaceutical research, have become a central bridge enabling nucleic acid therapeutics to progress from laboratory studies toward practical application. Compared with traditional liposomes, LNPs demonstrate clear advantages in structural complexity and functional customization, allowing efficient encapsulation and protection of fragile biomacromolecules from degradation.
Lipid nanoparticles are submicron colloidal delivery systems composed of multiple functional lipid molecules, with particle sizes typically ranging from 10 nm to 100 nm. Unlike conventional liposomes with an aqueous core structure, LNPs exhibit a highly organized solid internal architecture. This unique amorphous solid or liquid-crystalline physical state confers superior cargo-loading capacity.
Stable encapsulation of nucleic acid cargo: LNPs achieve high-density encapsulation of genetic materials such as mRNA, siRNA, or pDNA through electrostatic interactions between ionizable lipids and the phosphate backbone of nucleic acids. This physical barrier effectively blocks nuclease-mediated degradation in circulation and preserves the integrity of the genetic information.
Overcoming biological membrane barriers: Cell membranes possess hydrophobic and negatively charged properties that hinder the direct entry of hydrophilic, anionic nucleic acids. LNPs interact with cellular membranes via their hydrophobic surface and utilize endocytosis to drive delivery into target cells.
Precise intracellular release: A key aspect of LNP design is environmental responsiveness. During endosomal acidification, LNP components undergo protonation, inducing fusion and disruption of the endosomal and nanoparticle membranes, thereby enabling the precise release of nucleic acid cargo into the cytoplasm.
Among non-viral delivery systems, LNPs have become the most widely applied platform due to their distinctive physicochemical properties and biocompatibility. This preference arises from several key technical advantages.
High encapsulation efficiency and payload capacity: Compared with polymer-based delivery systems, LNPs prepared via microfluidic mixing can achieve nucleic acid encapsulation efficiencies exceeding 90 percent. Their compact internal organization allows high-density payloads within a very small particle volume, improving delivery efficiency per unit dose.
Tunable biodistribution properties: By adjusting lipid composition ratios or modifying surface ligands, the in vivo distribution behavior of LNPs can be significantly altered. For example, adsorption of endogenous ApoE proteins can promote liver-directed uptake, while the introduction of functional helper lipids can enable selective delivery to immune cell populations.
Lower immunogenicity and toxicity: Compared with viral vectors, LNPs do not present risks associated with integration into the host genome and contain no viral protein components, significantly reducing the likelihood of strong immune responses. The lipid components are largely biodegradable or endogenous in nature and can be metabolized and cleared after delivery.
Process scalability and consistency: Microfluidics-based T-mixer or staggered herringbone mixer (SHM) processes enable highly reproducible LNP production. These standardized preparation workflows ensure uniform particle size distributions with low polydispersity and provide a strong technical foundation for large-scale manufacturing.
Particle size is a primary factor determining the pharmacokinetic behavior of LNPs. Most highly efficient LNP formulations exhibit particle size distributions in the range of 60 nm to 100 nm.
Impact of particle size on biodistribution: Smaller particle sizes below 100 nm help reduce clearance by the mononuclear phagocyte system (MPS), thereby extending circulation time. In addition, specific size ranges can take advantage of hepatic sinusoidal fenestrations, enabling efficient penetration into hepatocytes.
Significance of the PDI: PDI is a dimensionless parameter used to describe particle size uniformity, typically ranging from 0 to 1. In pharmaceutical analysis, a PDI below 0.2 is generally considered indicative of a uniform size distribution with good dispersibility. Higher PDI values indicate excessive size heterogeneity, which can lead to inconsistent in vivo performance and accelerate aggregation and sedimentation of larger particles, ultimately compromising physical stability.
The electrical properties of LNPs, particularly the apparent acid dissociation constant (apparent pKa), play a decisive role in enabling endosomal escape.
Dynamic changes in surface charge: Under physiological pH conditions of approximately 7.4, LNPs typically maintain a near-neutral or slightly negative surface charge. This characteristic helps minimize nonspecific interactions with plasma proteins and improves overall biocompatibility.
Central role of apparent pKa: The apparent pKa is defined as the environmental pH at which 50 percent of the ionizable lipids within the LNP are protonated. For nucleic acid delivery applications, the optimal pKa range is generally between 6.2 and 6.5.
Mechanistic relevance: Upon entry into endosomes, where the pH decreases from 7.4 to approximately 5.5–6.0, the environmental pH falls below the apparent pKa. This induces protonation of ionizable lipids and generates a positive charge. The positively charged lipids interact with negatively charged endosomal membrane phospholipids, driving a structural transition from a lamellar phase to a hexagonal phase, which disrupts the endosomal membrane and enables nucleic acid release.
Encapsulation efficiency (EE%) and payload distribution are key indicators used to assess LNP quality and the maturity of the production process.
Table 1. Key physicochemical properties of LNPs and their impact on delivery performance.
| Physicochemical parameter | Ideal range or state | Impact on biological performance |
| Mean particle size (Z-average) | 60–100 nm | Influences tissue penetration, endocytic uptake rate, and circulation half-life |
| PDI | < 0.2 | Reflects batch consistency; lower PDI indicates higher physical stability |
| Apparent pKa | 6.2–6.5 | Regulates endosomal escape efficiency and directly affects transfection performance |
| Surface potential (zeta potential) | Near neutral under physiological conditions | Reduces off-target effects and toxicity caused by nonspecific interactions |
| EE% | > 90% | Maximizes payload utilization and reduces immunogenicity from unencapsulated nucleic acids |
Calculation and optimization of encapsulation efficiency: EE% represents the proportion of nucleic acid successfully encapsulated within nanoparticles relative to the total input amount. By optimizing the nitrogen-to-phosphate (N/P) ratio, defined as the molar ratio of ionizable amine groups in lipids to phosphate groups in nucleic acids, EE% can typically be increased to above 90 percent.
Consistency of payload distribution: Ideally, nucleic acids should be uniformly distributed within the multilayered or solid core structure of LNPs. Uneven payload distribution can result in a population of empty particles, while others become overloaded and structurally unstable.
BOC Sciences provides advanced lipid nanoparticle solutions engineered for efficient and targeted delivery. Our customizable platforms support enhanced cellular uptake and payload stability.
Before entering target cells, lipid nanoparticles undergo complex interactions at the biological interface. This process is not a simple physical contact but involves coordinated biological events, including protein corona formation, receptor recognition, and cytoskeleton-driven transport.
When LNPs enter the bloodstream or other biological fluids, their surfaces rapidly adsorb surrounding proteins, lipids, and other biomolecules, forming a dynamic protein corona. This interfacial interaction alters the original physicochemical properties of LNPs and confers a new biological identity.
Adsorption of endogenous ligands: For classical liver-directed LNPs, a key interfacial interaction is the adsorption of apolipoprotein E (ApoE) from plasma. The near-neutral surface of ionizable lipids favors specific ApoE binding, allowing ApoE to function as an endogenous guidance signal that facilitates cellular entry.
Opsonization and immune evasion: Complement proteins or immunoglobulins within the protein corona may trigger opsonization, leading to rapid clearance by the mononuclear phagocyte system. Therefore, modulation of interfacial interactions through optimization of PEG-lipid density is essential for prolonging circulation time.
LNPs enter cells primarily through receptor-mediated endocytosis. Due to variations in particle size distribution, surface charge, and cell type, uptake pathways exhibit substantial heterogeneity.
Table 2. Major cellular uptake pathways of LNPs and their characteristics.
| Endocytic pathway | Key regulators or receptors | Pathway characteristics | Typical contexts |
| Clathrin-mediated endocytosis (CME) | ApoE–LDLR interaction | Formation of ~100 nm invaginated vesicles with high specificity | Efficient uptake by hepatocytes |
| Macropinocytosis | Actin cytoskeleton remodeling | Non-specific uptake of large volumes of extracellular fluid and nanoparticles | High-capacity uptake in immune cells such as dendritic cells |
| Caveolin-mediated endocytosis | Caveolin-1 | Formation of flask-shaped membrane invaginations, potential avoidance of lysosomal degradation | Certain endothelial cells or specialized tissue delivery |
Fig.1 LNP Cellular Uptake and Endocytosis Pathways (BOC Sciences Original).
Receptor-mediated recognition: With ApoE assistance, LNPs bind to low-density lipoprotein receptors (LDLR) on the cell membrane and subsequently enter cells via clathrin-mediated endocytosis. This pathway is widely recognized as the dominant mechanism for mRNA–LNP uptake by hepatocytes.
Impact of uptake pathways on transfection efficiency: Studies indicate that LNPs entering via macropinocytosis often exhibit higher cargo release potential, whereas LNPs internalized through CME depend more strongly on subsequent endosomal acidification for effective escape. Differences in the relative contribution of these pathways across cell types directly determine LNP transfection performance in different tissues.
Designing an efficient LNP system is not a simple matter of mixing components but a precise molecular engineering process. Researchers must balance the physicochemical stability of nanoparticles with their biological functionality, fine-tuning each variable to maximize delivery efficiency while minimizing potential side effects.
Lipid selection and molar ratio: Different lipids play specific roles in LNPs. Ionizable lipids enable nucleic acid binding and endosomal escape, helper lipids and cholesterol maintain membrane stability, and PEG-lipids regulate surface hydrophobicity and prolong circulation time.
Ionizable lipid structure: Headgroup chemistry controls the apparent pKa, while the hydrophobic or branched tail influences membrane fluidity and perturbation. Unsaturated or branched tails typically enhance membrane disruption, significantly improving endosomal escape.
Precise component ratios: Lipid composition is customized based on nucleic acid type and length. The classic formulation is roughly 50:10:38.5:1.5, but for large mRNA constructs, increasing helper lipid content can stabilize the layered structure, and fine-tuning the N/P ratio optimizes payload encapsulation.
Core challenge: LNPs must remain highly stable in the extracellular environment while releasing their cargo rapidly inside cells.
Dynamic PEG dissociation: "PEG shedding" balances circulation stability with cellular uptake. Increasing PEG chain length can prevent particle aggregation, but overly stable PEG coatings may inhibit uptake. Designing PEG-lipids with specific dissociation rates ensures active surfaces are exposed upon reaching target cells.
Cholesterol rigidity control: Cholesterol fills membrane gaps, reducing nucleic acid leakage and maintaining particle integrity in circulation. Excess cholesterol increases membrane rigidity, hindering endosomal membrane rearrangement. Using cholesterol derivatives allows precise modulation of membrane fluidity, achieving a balance between stability and release kinetics.
Efficacy vs. toxicity: Increasing the proportion of ionizable lipids can enhance transfection efficiency but may trigger immune responses. Incorporating biodegradable ester bonds in lipids allows LNPs to degrade into non-toxic metabolites after delivery, mitigating toxicity.
Targeting vs. manufacturing complexity: Ligand modifications improve organ-specific delivery (e.g., lung, spleen, tumor) but increase synthesis complexity and batch-to-batch variability. Designs must balance tissue specificity with scalability and reproducibility.
Thermal stability vs. distribution convenience: LNP structures are temperature-sensitive. Developing thermally stable lipids or employing lyophilization techniques reduces dependence on ultra-low temperature cold chains, enabling easier global distribution.
Although LNPs offer significant advantages, their development faces multiple technical challenges in both research and industrial production. These issues directly affect delivery efficiency, formulation stability, and reproducibility, making careful control during design and manufacturing essential.
Particle instability: LNPs may experience structural loosening or partial disruption during storage or circulation due to uneven lipid interactions, insufficient surface modification, or changes in environmental conditions.
Aggregation risk: Inadequate electrostatic repulsion or uneven PEG coating can lead to particle aggregation, altering size distribution, reducing surface activity, and impairing delivery performance.
Key influencing factors: Particle size distribution, surface charge, PEG coverage density, and lipid composition are critical parameters that determine stability. Controlling these factors can minimize aggregation and sedimentation, enhancing circulation stability and shelf life.
Variable encapsulation efficiency: Different LNP batches may show variation in nucleic acid payload, often due to fluctuations in microfluidic mixing efficiency, N/P ratio, or lipid solution concentration during preparation.
Batch-to-batch variability: Key attributes such as particle size, PDI, surface charge, and encapsulation efficiency can vary across production batches, resulting in inconsistent biodistribution and delivery performance.
Optimization strategies: Precise control of raw material concentrations, mixing parameters, and process temperature, combined with standardized in-line monitoring, can significantly reduce batch variability and improve reproducibility and product quality.
To address the complex technical challenges in LNP development, BOC Sciences offers one-stop resources and technical support, helping researchers and pharmaceutical companies transition smoothly from early lipid screening to pilot-scale production. With extensive expertise in lipid chemistry and nanotechnology, we are committed to providing systematic solutions that combine professional rigor with practical operability.
Table 3. LNP Development and Characterization Services at BOC Sciences.
Core of LNP performance: The structure of lipid molecules. BOC Sciences provides comprehensive customization services to overcome the limitations of existing commercial formulations.
Novel ionizable lipid synthesis: We design lipid libraries with enhanced endosomal escape efficiency through molecular engineering. Custom synthesis of cationic and ionizable lipids is supported, including the introduction of biodegradable ester bonds, branched-chain optimization, and headgroup modifications, enabling clients to build proprietary delivery platforms.
Formulation ratio customization and optimization: Lipid components are screened based on nucleic acid type (mRNA, siRNA, pDNA). Beyond standard formulations, we use design-of-experiments (DoE) approaches to optimize the ratios of four lipid components and the N/P ratio in multiple dimensions, ensuring the delivery system is ideally matched to the specific biomolecule.
Accurate characterization is the foundation for evaluating LNP quality and performance. BOC Sciences is equipped with advanced analytical platforms, providing comprehensive reports that meet in-depth industry requirements.
Multidimensional size and morphology analysis: Dynamic light scattering (DLS) and cryo-electron microscopy (Cryo-EM) reveal particle microstructure. In addition to standard Z-average and PDI measurements, we provide visualized morphology analysis to confirm the presence of solid-core structures rather than simple multilamellar vesicles.
Electrochemical property assessment: Surface charge and apparent pKa measurements are used to evaluate in vivo behavior. Fluorescent probe methods, such as TNS, accurately determine the apparent pKa, helping researchers predict particle protonation in the endosome and guide endosomal escape optimization.
High encapsulation efficiency is critical for reducing dosage and improving therapeutic outcomes. BOC Sciences has extensive experience in optimizing payload processes.
Mixing process engineering optimization: Precise fluidic control techniques are used to achieve efficient nucleic acid encapsulation. Parameters for ethanol injection and microfluidic mixing are optimized to enhance electrostatic complexation between cationic lipids and anionic nucleic acids, maintaining encapsulation rates above 90%.
Payload consistency monitoring: Reducing the proportion of "empty" particles improves overall transfection efficiency. Fine control of fluid shear, mixing ratios, and buffer pH significantly decreases heterogeneity in payload distribution, ensuring that each particle carries an adequate amount of active material.
To address LNP instability during storage and transport, BOC Sciences provides targeted strategies for particle stabilization.
Surface chemistry modification and PEG optimization: Adjusting PEG-lipid concentration and structure reduces particle aggregation. For specific applications, we help clients select PEG lipids with varying molecular weights and dissociation rates, enhancing colloidal stability in circulation while balancing cellular uptake efficiency.
Advanced formulation protection: Lyophilization and the use of protective excipients improve physical and thermal stability. For long-term storage, we support the development of freeze-dried formulations and study cryoprotectants such as sugars to stabilize LNP structure, effectively preventing particle fusion during repeated freeze-thaw cycles or prolonged storage.
References
